期刊
NANOMEDICINE
卷 11, 期 4, 页码 359-375出版社
FUTURE MEDICINE LTD
DOI: 10.2217/nnm.15.201
关键词
human umbilical vein endothelial cells; intravascular specific site release; nanocomplexes; PAMAM G1; patency; pVEGF165 gene; restenosis; RGD peptide; targeting; transfection efficiency
资金
- National Natural Science Foundations of China [31170918]
Aim: To validate the efficacy of nanocomplexes from RGD-modified polyamidoamine (PAMAM G1) copolymer for prevention of restenosis. Materials & methods: Generation 1.0 polyamidoamine (PAMAM G1)-based copolymers (PGP) and RGD modified PGP (PGP-RGD) were synthesized and its properties were evaluated. Intravascular VEGF165 release tests were performed. Results: The PGP-RGD1 (2.6% grafting rate) exhibited lower cytotoxicity and larger combining ability with pDNA. The complexes had sizes of 80-160 nm and zeta potentials of 3-20 mV. Transfection efficiency of PGP-RGD1 complexes in human umbilical vein endothelial cells was larger than that of PGP complexes. Patency and expression level of artery in PGP-RGD1 group were higher than that in saline group. Conclusion: PGP-RGD1 will be a promising targeted gene vector.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据